As an obesity medicine physician scientist who regularly cares for patients with complex inflammatory conditions, this study reinforces what many of us have suspected clinically that the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss and may fundamentally alter the disease trajectory for some of our highest-risk patients, Stanford added in a news release
While genetic predisposition is just one piece of the puzzle, understanding these pathways can support a more informed discussion about whether a slower titration, lower maintenance dose, or different compounded formulation might optimize your safety and tolerability
The Bottom Line NAC is more than an antioxidant
Journal reference: Song G, Han H, Park S, et al
Not only that: Demand for GLP-1s is predicted to continue growing for at least the next 5 years, reaching $105 billion in 2030, according to one forecast
These symptoms can significantly impact daily comfort and quality of life